louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01359774: 31P-MRS and Huntington Disease
Official title: 31Phosphorus-Magnetic Resonance Spectroscopy and Huntington Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Huntington Disease
Keywords: Energy
Metabolism
Spectroscopy
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
First posted: 2011-05-25
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to identify and quantify a brain energy deficit in Huntington patients, using 31P-RMN spectroscopy.


Eligibility criteria: Inclusion Criteria:

* 5\<UHDRS\<50
* Age\>18 years
* Ability to undergo MR scanning
* Covered by french social security

Exclusion Criteria:

* Evidence of psychiatric disorder
* Attendant neurological disorder
* Contraindications to MRI (claustrophobia, metallic or material implants)
* Severe head injury
* Unable to understand the protocol
* Pregnancy
* Failure to give informed consent
* Subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent)
* Unwillingness to be informed in case of abnormal MRI

Primary outcomes:
measure: Brain energy deficit in Huntington patients
timeFrame: one year
Secondary outcomes:
measure: Correlating a brain energy deficit with (i) biochemical parameters and (ii) clinical parameters in Huntington patients
timeFrame: one year
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital de la Pitié-Salpetrière
Study officials:
affiliation: INSERM UMR S975 Institut du Cerveau et de la Moelle, AP-HP Département de Génétique, Université Pierre et Marie Curie, Paris France
name: Fanny Mochel, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011 Feb;121(2):493-9. doi: 10.1172/JCI45691. Epub 2011 Feb 1.
citation: Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One. 2007 Jul 25;2(7):e647. doi: 10.1371/journal.pone.0000647.
citation: Mochel F, Benaich S, Rabier D, Durr A. Validation of plasma branched chain amino acids as biomarkers in Huntington disease. Arch Neurol. 2011 Feb;68(2):265-7. doi: 10.1001/archneurol.2010.358. No abstract available.
Clinical trial NCT03257774: Evaluation of the Effect of Output on New Adhesives
Official title: A Pilot Evaluation of Newly Developed Adhesives and How They Are Impacted by Output
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ileostomy - Stoma
Lead sponsor: Coloplast A/S
Sponsor class: INDUSTRY
First posted: 2017-08-22
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The study investigates the impanct real output has on the adhesion of a new adhesive


Eligibility criteria: Inclusion Criteria:

1. Have given written informed consent
2. Be at least 18 years of age and have full legal capacity
3. Have had a stoma for more than one year
4. Have intact skin on the area used in the evalua-tion
5. Has a stoma with a diameter up to (≤) 35 mm
6. Have a peristomal area accessible for application of adhesive strips (assessed by investigating scientist)

Exclusion Criteria:

1. Currently receiving or have within the past 2 month received radio- and/or chemotherapy
2. Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment.
3. Are pregnant or breastfeeding
4. Having dermatological problems in the peristo-mal- or abdominal area (assessed by investigating scientist)
5. Actively participating in other interventional clinical investigations or have previously participated in this investigation

Primary outcomes:
measure: Trans epidermal water loss
timeFrame: 8 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Humlebæk
country: Denmark
facility: Coloplast A/S
Study officials:
affiliation: Head of preclinical department
name: Lene F Nielsen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01401374: Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo
Official title: Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vitiligo Vulgaris
Keywords: Vitiligo Vulgaris
Autoimmunity
Thyroid Disease
Lead sponsor: St. Luke's-Roosevelt Hospital Center
Sponsor class: OTHER
First posted: 2011-07-25
Enrollment: 3258
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals self-reporting vitiligo vulgaris and controls who do not have vitiligo vulgaris

Brief summary: The study is an on-line survey posted on survey monkey that addresses some demographic and environmental issues that could potentially relate to vitiligo vulgaris onset or disease exacerbation.

Detailed description: The survey is designed to look at some issues that are pertinent to individuals with vitiligo, including access to care, severity of disease, under-reported disease activity, causative and exacerbating factors and co-morbid illnesses.

Eligibility criteria: Inclusion Criteria:

* Ability to complete survey

Exclusion Criteria:

* Inability to complete survey

Primary outcomes:
measure: Correlation of Disease State in Vitiligo with Clinical and Psychological Measures
timeFrame: Self-reported retrospective single survey
Secondary outcomes:
Other outcomes:
Locations:
city: New york
country: United States
facility: St. Luke's-Roosevelt Hospital Center
state: New York
Study officials:
affiliation: St. Luke's-Roosevelt Hospital Center
name: Nanette Silverberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Silverberg JI, Reja M, Silverberg NB. Regional variation of and association of US birthplace with vitiligo extent. JAMA Dermatol. 2014 Dec;150(12):1298-305. doi: 10.1001/jamadermatol.2014.899.
citation: Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol. 2014 May-Jun;31(3):309-18. doi: 10.1111/pde.12226. Epub 2013 Oct 18.
citation: Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013 Feb;149(2):159-64. doi: 10.1001/jamadermatol.2013.927.
Clinical trial NCT03424174: Clinical Outcome and Cytokine Expression After TKA
Official title: Clinical Outcome and Cytokine Expression in Blood After Coated in Comparison to Uncoated TKA
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Osteoarthritis
Keywords: TKA, cytokine, coating
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2018-02-06
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparison of coated and uncoated TKA with regard to cytokine expression and clinical results

Detailed description: Comparison of coated and uncoated TKA with regard to cytokine expression and clinical results at 3 months, 1 year and 3 years after surgery

Eligibility criteria: Inclusion Criteria:

* Primary and secondary osteoarthritis
* understanding of german language

Exclusion Criteria:

* necessity of constrained TKA
* existence of other joint implants

Primary outcomes:
measure: cytokine expression
timeFrame: pre-op, 1 and 3 years post-op
Secondary outcomes:
measure: Function assessed with Knee Society Score
timeFrame: pre-op, 3 months, 1 and 3 years post-op
measure: Patient reported outcome assessed with Oxford Knee Score
timeFrame: pre-op, 3 months, 1 and 3 years post-op
measure: Quality of life assessed with EQ 5D
timeFrame: pre-op, 3 months, 1 and 3 years post-op
measure: Activity assessed with UCLA activity score
timeFrame: pre-op, 3 months, 1 and 3 years post-op
Other outcomes:
measure: adverse events
timeFrame: 3 month, 1 year and 3 years post-op
Locations:
city: Dresden
country: Germany
facility: University Center of Orthopaedics and Traumatology, University Medicine Carl Gustav Carus Dresden, TU Dresden
state: Saxonia
Study officials:
affiliation: University Center of Orthopaedics and Traumatology, University Medicine Carl Gustav Carus Dresden
name: Jörg Lützner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00919074: Comparison of Double Wire Technique With Pancreatic Duct Stent Placement for Difficult Bile Duct Cannulation
Official title: Comparison of Double Wire Technique With Pancreatic Duct Stent Placement for Difficult Bile Duct Cannulation: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Bile Duct Cannulation
Keywords: Patients undergoing endoscopic retrograde cholangiopancreatography for the first time
Particular focus on patients who meet predefined criteria for a difficult bile duct cannulation
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: Northwestern University
name: University of Oklahoma
First posted: 2009-06-12
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research project will compare the use of the double wire technique with the placement of a pancreatic duct (PD) stent to achieve deep biliary cannulation without the use of a precut papillotomy. Currently, the data supporting either of these approaches is limited to the referenced case series. More data on the success and complication rates of these techniques are needed. The investigators believe either of these approaches would be preferred by less experienced endoscopists to precut papillotomy. Consequently, it is important to differentiate these techniques and identify which patients may benefit from one or both.


Eligibility criteria: Inclusion Criteria:

* First time ERCP

Exclusion Criteria:

* Successful bile duct cannulation within six minutes
* Planned pancreatic duct therapy
* Planned pancreatobiliary manometry
* Prior successful ERCP

Primary outcomes:
measure: Cannulation success rate
timeFrame: Cannulation is assessed during the index procedure; procedure-related complications are assessed within one week of the procedure
Secondary outcomes:
measure: Complication rate
timeFrame: One week
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
city: St. Louis
country: United States
facility: Washington University in St. Louis
state: Missouri
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Sciences Center
state: Oklahoma
Study officials:
affiliation: Washington University School of Medicine
name: Riad R Azar, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cote GA, Mullady DK, Jonnalagadda SS, Keswani RN, Wani SB, Hovis CE, Ammar T, Al-Lehibi A, Edmundowicz SA, Komanduri S, Azar RR. Use of a pancreatic duct stent or guidewire facilitates bile duct access with low rates of precut sphincterotomy: a randomized clinical trial. Dig Dis Sci. 2012 Dec;57(12):3271-8. doi: 10.1007/s10620-012-2269-2. Epub 2012 Jun 26.
Clinical trial NCT05822674: Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio
Official title: A Preliminary Clinical Study on the Effects of Oral Hypoglycemic Agents on the Stress Hyperglycemic Ratio in Type 2 Diabetes Patients in the Absence of Serious Illness
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 2 Diabetes
Keywords: Stress hyperglycemia ratio
Sitagliptin
Empagliflozin
Lead sponsor: University of Diyala
Sponsor class: OTHER
First posted: 2023-04-21
Enrollment: 80
Sex: ALL
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Known cases of type 2 diabetes who were attending the diabetes centers and private clinics seeking for diabetes control and follow-up.

The authors discussed with the participants about the study design and outcomes

Brief summary: A blood glucose level of equal to or greater than 180 mg/dL that occurred during stress in a patient without diabetes mellitus (DM) is termed stress hyperglycemia (SH). The stress hyperglycemia ratio (SHR) is defined as the fasting blood glucose divided by the blood glucose level that is calculated from the glycosylated hemoglobin (HBA1c) value on admission. A significantly higher SHR is associated with worse prognostic biomarkers in diabetic patients with complications

Detailed description: Stress hyperglycemia (SH) is an increase in circulating glucose levels in biological fluids as a physiological response to stress in diabetic patients who are known or newly diagnosed, or a pathological condition associated with in-hospital-related hyperglycemia.

Interventions. Through their pleiotropic effects, some oral hypoglycemic agents improved stress hyperglycemia. When compared to non-SGLT-I (sodium glucose transporter-inhibitor) users, diabetic patients who used (SGLT-I) and had an acute myocardial infarction had less prevalent stress hyperglycemia, a smaller infarct size, and evidence of a low inflammatory response. The rationale this study is to evaluate the SHR in T2D patients who do not have serious illnesses and are managed with oral hypoglycemic agents

Eligibility criteria: Inclusion Criteria:

* Age ≥35 years
* Diagnosis of Type 2 diabetes
* Absence of serious illnesses
* No evidence of trauma

Exclusion Criteria:

* Overt complications of diabetes
* Any participant used antibiotics for infectious diseases
* Any participant used non-steroidal antiinflammatory drugs
* Current or past history of mental diseases
* Current hematological diseases
* Pregnancy
* Nursing mothers

Primary outcomes:
measure: Stress hyperglycemia Ratio
timeFrame: 10 week
Secondary outcomes:
measure: Hematological indices
timeFrame: 10 week
measure: Inflammatory markers
timeFrame: 10 week
Other outcomes:
Locations:
city: Baqubah
country: Iraq
facility: College of Medicine, University of Diyala
state: Diyala
Study officials:
affiliation: The Dean College of Medicine, University of Diyal
name: Ismail Latif
role: STUDY_DIRECTOR
References:
Clinical trial NCT00189774: Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Type 2 Diabetes Mellitus
Diabetes Mellitus, Type II
Keywords: nateglinide
pioglitazone
combination drug therapy
treatment
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Ajinomoto USA, INC.
First posted: 2005-09-19
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes mellitus under the treatment with pioglitazone

Exclusion Criteria:

* Patients who cannot follow the diet therapy and/or exercise therapy
* Type 1 diabetes mellitus

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chubu region
country: Japan
city: Chugoku region
country: Japan
city: Hokkaido region
country: Japan
city: Kanto region
country: Japan
city: Kinki region
country: Japan
city: Kyushu region
country: Japan
city: Tohoku region
country: Japan
Study officials:
affiliation: Astellas Pharma Inc
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00004665: Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Systemic Lupus Erythematosus
Keywords: arthritis & connective tissue diseases
immunologic disorders and infectious disorders
rare disease
systemic lupus erythematosus
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: Northwestern University
First posted: 2000-02-25
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: OBJECTIVES:

I. Evaluate the long-term safety and tolerance of a synthetic formulation of dehydroepiandrosterone, GL701, in patients with systemic lupus erythematosus who have completed a prior GL701 protocol.

Detailed description: PROTOCOL OUTLINE: Patients receive daily oral dehydroepiandrosterone for 12 months. The dose is adjusted based on disease activity and tolerance of treatment.

Patients are followed every 3 months.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Systemic lupus erythematosus by American College of Rheumatology criteria Mild to moderate disease characterized as follows: Prednisone dose (or equivalent) 10 to 30 mg/day No daily dose 1 mg/kg or greater No alternate-day regimen Failed prednisone taper in last 12 months and dose stable for at least 6 weeks prior to entry OR No attempt to taper in last 12 months and dose stable for at least 3 months prior to entry Prior completion of dehydroepiandrosterone (DHEA) study required No prior participation in double-blind DHEA study at Stanford University --Prior/Concurrent Therapy-- No concurrent immunosuppressants No concurrent participation in other clinical studies No investigational agents within the longer of 30 days or 10 half-lives of the agent At least 3 months since immunosuppressants, including: Adrenocorticotropin hormone Androgens Cyclophosphamide Azathioprine Intravenous immune globulin At least 1 month since change in dose of nonsteroidal anti-inflammatory drugs or hydroxychloroquine --Patient Characteristics-- Age: 18 and over Sex: Female only Performance status: Not specified Other: No hypersensitivity to DHEA or inactive ingredient in GL701 formulation, i.e., cornstarch, lactose, or magnesium stearate No condition that would prevent adequate compliance with study No history of breast cancer or reproductive tract malignancy Negative pregnancy test required within 2 weeks prior to entry Reliable contraception required of fertile women No estrogen-containing oral contraceptive

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Northwestern University
name: Rosalind Ramsey-Goldman
role: STUDY_CHAIR
References:
Clinical trial NCT02392065: Chronic Obstructive Pulmonary Disease as a Predictor of Mortality in Cardiac Surgery
Official title: Chronic Obstructive Pulmonary Disease as a Predictor of 2-year Mortality in Patients Undergoing Coronary Artery Bypass Graft Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Obstructive Pulmonary Disease
Cardiac Surgery
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
Sponsor class: NETWORK
First posted: 2015-03-18
Enrollment: 1100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients scheduled for coronary artery bypass surgery during one year will be screened and approached

Brief summary: To estimate prevalence of chronic obstructive pulmonary disease (COPD) in cardiac surgery population and establish links between COPD status, as assessed through pulmonary functional tests, and 2-year mortality


Eligibility criteria: Inclusion Criteria:

* written informed consent, planned elective coronary artery bypass graft surgery

Exclusion Criteria:

* contraindications to pulmonary functional tests, emergency surgery, recent or ongoing myocardial infarction, angina

Primary outcomes:
measure: All-cause mortality
timeFrame: Two years
Secondary outcomes:
Other outcomes:
Locations:
city: Novosibirsk
country: Russian Federation
facility: Novosibirsk Research Institute of Circulation Pathology
Study officials:
affiliation: Novosibisrk Research Institute of Circulation Pathology
name: Vladimir Lomivorotov, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05079165: Covid Vaccination in Liver Transplantation
Official title: EVALUATION OF THE RESPONSE TO mRNA SARS-CoV-2 VACCINE IN A COHORT OF LIVER TRANSPLANTED OR LISTED PATIENTS
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19
Keywords: COVID-19
SARS-COV-2
Coronavirus Vaccine
COVID-19 Pandemic
COVID-19 Virus Disease
SARS-CoV-2 Infection
Solid organ transplant
mRNA vaccine
MODERNA
liver transplant
Serological testing
serological response
SARS-CoV-2 mRNA vaccine
Anti-SARS-CoV-2 IgG antibodies
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2021-10-15
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Liver transplanted adult patients for \> 6 months after transplantation

Brief summary: The goal of this retrospective study is to evaluate the proportion of seroconversion after 2 doses mRNA anti-SARS-CoV2 vaccination in a cohort of high risk liver transplanted patients.

Seroprevalence is a secondary objective in order to identify seronegative patients with a history of COVID-19 (ie who lost antibodies) and seropositive patients with no history of COVID-19.

The hypothesis is that the degree of immunosuppression is determinant on the seroconversion rate and therefore, although at higher risk of severe forms of COVID-19, liver transplanted patients have a lower chance of being protected after vaccination.

Seroconversion rate in previously seronegative and with no history of COVID-19 liver transplanted patients is the main evaluation criteria.

The factors associated with the absence of seroconversion will be identified as a potential tool to better adapt the vaccination strategy in this population.

The rate of seroconversion after the 1st dose will also be evaluated. Safety of the 1st and 2nd injection will be reported as well as their value to predict seroconversion.

A control group of patients listed for transplantation will also be included both in the seroprevalence and the seroconversion analysis.

Persistance of the antibodies in long-term after transplantation and after transplantation for the patients who have been vaccinated before transplantation will also be reported.


Eligibility criteria: Inclusion criteria:

* Liver transplanted patients for \> 6 months after transplantation
* Listed cirrhotic patients
* Age \>18 years-old
* Consent for vaccination with mRNA vaccine

Exclusion criteria:

* Vaccination with non mRNA anti-SARS-CoV-2 vaccine
* Expressed opposition to participation to the study

Primary outcomes:
measure: Retrospective description of the serological response to the anti-SARS-CoV-2 mRNA vaccine
timeFrame: Files analysed retrospectively from January 18, 2020 to April 30, 2021 will be examined]
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service deChirurgie Générale Hépatique-Endocrinienne,et transplantation - Hôpitaux Universitaires de Strasbourg
Study officials:
References: